Physician profile
Philip Kim
NPI 1356781132
$4,023.87
in general payments reported to CMS, 2019-2025
27 companies · $1,768 in 2025
The $1,768 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $324 · 2021: $83.79 · 2022: $1,057 · 2023: $141 · 2024: $392 · 2025: $1,768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,552 · Consulting Fee: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,551.76 |
| Consulting Fee | $750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Envista Holdings Corporation | $750.00 | 2025 | Education |
| Biohaven Pharmaceutical Holding Company LTD. | $506.44 | 2022 | |
| Janssen Pharmaceuticals, INC | $366.80 | 2019-2022 | |
| Novo Nordisk INC | $349.76 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $307.30 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $250.07 | 2020-2025 | Jardiance |
| Amgen INC. | $195.56 | 2022-2025 | Tepezza, Otezla, Repatha |
| Sumitomo Pharma America, INC. | $173.73 | 2025 | Gemtesa |
| Mml US, INC. | $144.35 | 2022 | |
| Glaxosmithkline, LLC. | $134.37 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $117.54 | 2020-2023 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $102.68 | 2020-2022 | |
| Lexicon Pharmaceuticals, INC. | $99.04 | 2024 | |
| Lilly USA, LLC | $88.59 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $78.59 | 2022-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $73.96 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $66.58 | 2020-2022 | |
| Insmed, INC. | $54.11 | 2025 | Brinsupri, Arikayce |
| Exact Sciences Corporation | $46.97 | 2025 | Cologuard Collection Kit |
| Dexcom, INC. | $23.02 | 2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $22.24 | 2023 | Rexulti |
| Esperion Therapeutics, INC. | $20.36 | 2024 | Nexletol |
| Amarin Pharma, INC. | $17.67 | 2020 | |
| Opko Pharmaceuticals, LLC | $17.52 | 2022 | |
| Boston Scientific Corporation | $16.62 | 2023 | Lithoclast |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.